225 related articles for article (PubMed ID: 21416942)
21. CYP450 Epoxygenase Metabolites, Epoxyeicosatrienoic Acids, as Novel Anti-Inflammatory Mediators.
Shi Z; He Z; Wang DW
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744996
[TBL] [Abstract][Full Text] [Related]
22. Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs.
Zhang Y; Gao L; Yao B; Huang S; Zhang Y; Liu J; Liu Z; Wang X
Life Sci; 2022 Dec; 310():121122. PubMed ID: 36309225
[TBL] [Abstract][Full Text] [Related]
23. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase.
Liu Y; Zhang Y; Schmelzer K; Lee TS; Fang X; Zhu Y; Spector AA; Gill S; Morisseau C; Hammock BD; Shyy JY
Proc Natl Acad Sci U S A; 2005 Nov; 102(46):16747-52. PubMed ID: 16267130
[TBL] [Abstract][Full Text] [Related]
24. Phosphatase activity of soluble epoxide hydrolase.
Kramer J; Proschak E
Prostaglandins Other Lipid Mediat; 2017 Nov; 133():88-92. PubMed ID: 28729091
[TBL] [Abstract][Full Text] [Related]
25. The involvement of soluble epoxide hydrolase in the development of cardiovascular diseases through epoxyeicosatrienoic acids.
Jiang S; Han S; Wang DW
Front Pharmacol; 2024; 15():1358256. PubMed ID: 38628644
[TBL] [Abstract][Full Text] [Related]
26. Soluble epoxide hydrolase deficiency attenuates lipotoxic cardiomyopathy via upregulation of AMPK-mTORC mediated autophagy.
Wang L; Zhao D; Tang L; Li H; Liu Z; Gao J; Edin ML; Zhang H; Zhang K; Chen J; Zhu X; Wang D; Zeldin DC; Hammock BD; Wang J; Huang H
J Mol Cell Cardiol; 2021 May; 154():80-91. PubMed ID: 33378686
[TBL] [Abstract][Full Text] [Related]
27. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
28. Soluble epoxide hydrolase inhibition enhances production of specialized pro-resolving lipid mediator and promotes macrophage plasticity.
Abdalla HB; Alvarez C; Wu YC; Rojas P; Hammock BD; Maddipati KR; Trindade-da-Silva CA; Soares MQS; Clemente-Napimoga JT; Kantarci A; Napimoga MH; Van Dyke TE
Br J Pharmacol; 2023 Jun; 180(12):1597-1615. PubMed ID: 36508312
[TBL] [Abstract][Full Text] [Related]
29. Soluble epoxide hydrolase and ischemic cardiomyopathy.
Zhao TT; Wasti B; Xu DY; Shen L; Du JQ; Zhao SP
Int J Cardiol; 2012 Mar; 155(2):181-7. PubMed ID: 21704394
[TBL] [Abstract][Full Text] [Related]
30. Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?
Bellien J; Joannides R; Richard V; Thuillez C
Pharmacol Ther; 2011 Jul; 131(1):1-17. PubMed ID: 21514320
[TBL] [Abstract][Full Text] [Related]
31. Epoxide hydrolases in the rat epididymis: possible roles in xenobiotic and endogenous fatty acid metabolism.
DuTeaux SB; Newman JW; Morisseau C; Fairbairn EA; Jelks K; Hammock BD; Miller MG
Toxicol Sci; 2004 Apr; 78(2):187-95. PubMed ID: 14737000
[TBL] [Abstract][Full Text] [Related]
32. Soluble epoxide hydrolase inhibitors and cardiovascular diseases.
Wang ZH; Davis BB; Jiang DQ; Zhao TT; Xu DY
Curr Vasc Pharmacol; 2013 Jan; 11(1):105-11. PubMed ID: 22303912
[TBL] [Abstract][Full Text] [Related]
33. Vascular localization of soluble epoxide hydrolase in the human kidney.
Yu Z; Davis BB; Morisseau C; Hammock BD; Olson JL; Kroetz DL; Weiss RH
Am J Physiol Renal Physiol; 2004 Apr; 286(4):F720-6. PubMed ID: 14665429
[TBL] [Abstract][Full Text] [Related]
34. Lipid sulfates and sulfonates are allosteric competitive inhibitors of the N-terminal phosphatase activity of the mammalian soluble epoxide hydrolase.
Tran KL; Aronov PA; Tanaka H; Newman JW; Hammock BD; Morisseau C
Biochemistry; 2005 Sep; 44(36):12179-87. PubMed ID: 16142916
[TBL] [Abstract][Full Text] [Related]
35. The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases.
Xu X; Li R; Chen G; Hoopes SL; Zeldin DC; Wang DW
Adv Nutr; 2016 Nov; 7(6):1122-1128. PubMed ID: 28140329
[TBL] [Abstract][Full Text] [Related]
36. Glimepiride, a novel soluble epoxide hydrolase inhibitor, protects against heart failure via increasing epoxyeicosatrienoic acids.
Zhao C; Jiang X; Peng L; Zhang Y; Li H; Zhang Q; Wang Y; Yang F; Wu J; Wen Z; He Z; Shen J; Chen C; Wang DW
J Mol Cell Cardiol; 2023 Dec; 185():13-25. PubMed ID: 37871528
[TBL] [Abstract][Full Text] [Related]
37. Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance.
Luria A; Bettaieb A; Xi Y; Shieh GJ; Liu HC; Inoue H; Tsai HJ; Imig JD; Haj FG; Hammock BD
Proc Natl Acad Sci U S A; 2011 May; 108(22):9038-43. PubMed ID: 21571638
[TBL] [Abstract][Full Text] [Related]
38. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.
Xu X; Zhang XA; Wang DW
Adv Drug Deliv Rev; 2011 Jul; 63(8):597-609. PubMed ID: 21477627
[TBL] [Abstract][Full Text] [Related]
39. Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase.
EnayetAllah AE; Luria A; Luo B; Tsai HJ; Sura P; Hammock BD; Grant DF
J Biol Chem; 2008 Dec; 283(52):36592-8. PubMed ID: 18974052
[TBL] [Abstract][Full Text] [Related]
40. Epoxyeicosatrienoic acids and soluble epoxide hydrolase in physiology and diseases of the central nervous system.
Kuo YM; Lee YH
Chin J Physiol; 2022; 65(1):1-11. PubMed ID: 35229747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
